Texting Trial Participants Without Creating a Compliance Problem

Texting is the highest-response channel most sites have. It's also the channel where the compliance exposure is easiest to overlook, because a coordinator sending a message from a phone doesn't feel like they're doing regulated marketing. Sometimes they are.

Here's what actually matters, in the order it tends to bite sites.

Consent to text is a separate question from study consent

Informed consent covers participation in research. It does not, by itself, authorize you to send SMS to someone's mobile number. Under U.S. telemarketing rules, recruitment texts to a prospect who found you through an ad are generally treated as promotional — which means you need prior express written consent captured before the first message.

Practically, that means your screening form or landing page needs a checkbox (not pre-checked) with language that names your site, states that message frequency varies, that message and data rates may apply, and that consent isn't a condition of participation. Keep the timestamp, the IP address, and the exact wording shown. If a complaint ever lands, the wording at the moment of consent is the evidence.

Once someone is an enrolled participant, texts about visit scheduling, dosing reminders, and study logistics sit on much firmer ground as transactional communication. The trap is mixing the two — sending an enrolled participant a message about a different study you're recruiting for. That's a new promotional contact, and it needs its own consent.

Opt-outs have to work immediately and everywhere

STOP must stop everything. Sites that run separate systems — one platform for recruitment, a scheduling tool for reminders, a coordinator's personal cell for the hard-to-reach — routinely fail this, because the opt-out only registers in one place.

Common fixes:

• One system of record for contactability status, checked before any send
• Opt-out honored across all studies, not just the one they replied to
• A documented process for logging manual opt-outs ("told me at the visit to stop texting")
• Include opt-out language in the first message of every new sequence, not just once

PHI in a text message

HIPAA doesn't ban texting PHI, but it requires reasonable safeguards, and it requires that the individual be informed of the risk if they've asked to be contacted that way. Document that they requested SMS and were told it isn't secure.

Then minimize anyway. Good practice:

1. Never name the indication in an unsolicited message. "Following up on the study you inquired about" beats naming the condition.
2. No lab values, no diagnoses, no medication names.
3. No photos of documents.
4. For anything clinical, move to phone or portal.

The IRB piece people forget

Recruitment materials require IRB review, and that includes SMS templates. Not just the ad that generated the lead — the actual text a prospect receives. Submit your sequence as a set of templates with bracketed variables, and get approval for the set. Then don't improvise. A coordinator rewriting an approved message on the fly is using an unapproved recruitment material, even if the edit was harmless.

Build a small library: approved templates by study and stage, plus a short list of pre-approved free-text uses (confirming an appointment time, answering a logistics question). Everything outside that library goes to phone or email, where the conversational latitude is better understood.

What to keep

Audit-ready texting means you can produce, for any contact: the consent record, every message sent with timestamps, the approved template it matched, and the current opt-out status. If that takes more than a couple of minutes to assemble, fix the record-keeping before you scale the volume.